BioCentury
ARTICLE | Finance

Deciphering Dicerna's future

Influx of cash, crossover investors have Dicerna looking to 2014 IPO

August 5, 2013 7:00 AM UTC

Dicerna Pharmaceuticals Inc.'s $60 million series C round last week attracted a syndicate of crossover investors that could usher the second-generation RNAi play to a public listing by this time next year.

New investor RA Capital led the round with participation from two other crossover investors - Brookside Capital and Deerfield Capital - as well as Omega Funds. Existing investors Abingworth, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One also participated...